Bevacizumab/nivolumabThrombotic microangiopathy and hypertension: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1949卷 / 1期

关键词：

D O I：

10.1007/s40278-023-36084-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：104 / 104

相关论文

共 50 条

[41] Bevacizumab/denosumabOsteonecrosis of the jaw: 2 case reports
[J]. Reactions Weekly, 2017, 1653 (1) : 72 - 72
[42] Bevacizumab/irinotecanNausea and vomiting: 2 case reports
[J]. Reactions Weekly, 2017, 1644 (1) : 57 - 57
[43] Bevacizumab/carboplatinHypertension and proteinuria: 2 case reports
[J]. Reactions Weekly, 2019, 1754 (1) : 82 - 82
[44] Bevacizumab/sunitinibRenal disorders: 2 case reports
[J]. Reactions Weekly, 2023, 1956 (1) : 104 - 104
[45] Bevacizumab/pemetrexedVarious toxicities: 2 case reports
[J]. Reactions Weekly, 2021, 1865 (1) : 115 - 115
[46] Bevacizumab/cetuximabRash, hypertension, gastrointestinal bleed, and headache: 6 case reports
[J]. Reactions Weekly, 2016, 1585 (1) : 52 - 52
[47] Bevacizumab/ranibizumabOcular hypertension following intravitreal administration: 23 case reports
[J]. Reactions Weekly, 2012, 1414 (1) : 15 - 15
[48] Bevacizumab/oxaliplatin/ramucirumabThrombotic microangiopathy: case report
[J]. Reactions Weekly, 2019, 1739 (1) : 67 - 67
[49] Fludarabine/melphalan/cyclophosphamideAcute respiratory distress syndrome, thrombotic microangiopathy and pulmonary arterial hypertension: 2 case reports
[J]. Reactions Weekly, 2017, 1645 (1) : 137 - 137
[50] Bevacizumab/capecitabineProteinuria and hypertension: 2 case report
[J]. Reactions Weekly, 2022, 1887 (1) : 150 - 150

← 1 2 3 4 5 →